Together these data suggest that enhanced Socs1 expression during hyperglycemia is detrimental to skin host defense and that iKIR treatment could represent host-directed immunotherapy to treat these antibiotic-resistant pathogens in the skin. The gene discussed is SOCS1; the disease is Hyperglycemia.